Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect)

PHASE3CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

December 15, 2017

Study Completion Date

June 1, 2018

Conditions
Cervical Spondylotic Myelopathy
Interventions
DRUG

riluzole

50mg BID orally for 14 days prior to surgery and 28 days after the surgery

DRUG

Placebo medication

50mg BID orally for 14 days prior to surgery and 28 days after the surgery

Trial Locations (21)

19107

Rothman Institute Orthopaedics, Philadelphia

Thomas Jefferson University, Philadelphia

22908

University of Virginia, Charlottesville

30329

Emory University School of Medicine, Atlanta

43210

The Ohio State University, Columbus

55905

Mayo Clinic, Rochester

60612

Rush University Medical Center, Chicago

63110

Washington University Orthopaedics, St Louis

66160

Kansas University Medical Center, Kansas City

70803

Louisiana State University, Baton Rouge

84108

University of Utah, Salt Lake City

85013

Barrow Neurological Institute, Phoenix

94143

University of California - San Francisco, San Francisco

95816

UC Davis Spine Center, Sacramento

98104

Harborview Medical Center, Seattle

T2N-2T9

University of Calgary, Calgary

M5B 1W8

St. Michael's Hospital, Toronto

M5T 2S8

University of Toronto Hospital, Toronto

H3H 2L9

McGill University Health Centre, Montral

H3A 2B4

Montreal Neurological Institute, Montreal

S7N 0W8

University of Saskatchewan, Royal University Hospital, Saskatoon

All Listed Sponsors
lead

AOSpine North America Research Network

NETWORK

NCT01257828 - Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) | Biotech Hunter | Biotech Hunter